Natali_Mis / iStockphoto.com
CRISPR is likely to be among the hot topics at the LSPN North America conference in Boston, as WIPR finds out.
Duane Marks, patent counsel in bio-products at Eli Lilly and Company, is one of the expert speakers attending the Life Sciences Patent Network (LSPN) North America conference in Boston on April 26.
As well as these expert speakers, focused roundtable sessions will allow delegates to delve into the latest developments in the global patent landscape and share predictions on their long-term impact in the sector. As the first in the 2018 series, LSPN North America’s overall focus is protecting innovation in the changing life sciences landscape.
The CRISPR patent struggle remains a hot topic, even more so since the European Patent Office revoked the Broad Institute’s patent relating to fundamental aspects of the CRISPR/Cas9 technology. At the first LSPN conference since January’s decision, the much-discussed verdict in the CRISPR dispute will be a major talking point, as will the landscape in the US.
Life Sciences Patent Network North America, LSPN conference, Life Sciences Intellectual Property Review conference, CRISPR